{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:10:34Z","timestamp":1782789034197,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101071041"],"award-info":[{"award-number":["101071041"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:04:37Z","timestamp":1730257477000},"page":"2997-3005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina"],"prefix":"10.1016","volume":"33","author":[{"given":"Fabio","family":"Dell\u2019Aquila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Di Cunto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Marrocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Notaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Nusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0832-2472","authenticated-orcid":false,"given":"Alberto","family":"Auricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.10.019_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0161-6420(81)35031-3","article-title":"The Natural History of Gyrate Atrophy of the Choroid and Retina","volume":"88","author":"Takki","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2024.10.019_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0161-6420(00)00587-X","article-title":"Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase","volume":"108","author":"Peltola","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2024.10.019_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0305-0491(87)90075-7","article-title":"Comparison of ornithine aminotransferase activities in the pigment epithelium and retina of vertebrates","volume":"88","author":"Ratzlaff","year":"1987","journal-title":"Comp. Biochem. Physiol. B"},{"key":"10.1016\/j.ymthe.2024.10.019_bib4","first-page":"24","article-title":"Regional expression of disease-related genes in human and monkey retina","volume":"4","author":"Bernstein","year":"1998","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2024.10.019_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/abio.1994.1574","article-title":"Assay of Ornithine Aminotransferase with Ninhydrin","volume":"223","author":"Kim","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymthe.2024.10.019_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0161-6420(81)35030-1","article-title":"Systemic Manifestations of Gyrate Atrophy of the Choroid and Retina","volume":"88","author":"Kaiser-Kupfer","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2024.10.019_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(73)90667-3","article-title":"Raised plasma-ornithine and gyrate atrophy of the choroid and retina","volume":"1","author":"Simell","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.10.019_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2020.140555","article-title":"Deficit of human ornithine aminotransferase in gyrate atrophy: Molecular, cellular, and clinical aspects","volume":"1869","author":"Montioli","year":"2021","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"10.1016\/j.ymthe.2024.10.019_bib9","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1172\/JCI118730","article-title":"A mouse model of gyrate atrophy of the choroid and retina: Early retinal pigment epithelium damage and progressive retinal degeneration","volume":"97","author":"Wang","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.10.019_bib10","first-page":"983","article-title":"Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration","volume":"2","author":"Wang","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.019_bib11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1073\/pnas.97.3.1224","article-title":"Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina","volume":"97","author":"Wang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.019_bib12","first-page":"196","article-title":"Gyrate Atrophy of Choroid and Retina: The Ocular Disease Progresses in juvenile Patients despite Normal or Near Normal Plasma Ornithine Concentration","volume":"100","author":"Vannas-Sulonen","year":"2002","journal-title":"J. Indian Med. Assoc."},{"key":"10.1016\/j.ymthe.2024.10.019_bib13","first-page":"146","article-title":"Gyrate atrophy of the choroid and retina: Further Experience With Long-term Reduction of Ornithine Levels in Children","volume":"120","author":"Kaiser-Kupfer","year":"2002","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ymthe.2024.10.019_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10633-014-9426-1","article-title":"OAT mutations and clinical features in two Japanese brothers with gyrate atrophy of the choroid and retina","volume":"128","author":"Katagiri","year":"2014","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.ymthe.2024.10.019_bib15","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217033","article-title":"Liver-directed gene therapy for ornithine aminotransferase deficiency","volume":"15","author":"Boffa","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.10.019_bib16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ymthe.2006.03.005","article-title":"Safety of Recombinant Adeno-Associated Virus Type 2-RPE65 Vector Delivered by Ocular Subretinal Injection","volume":"13","author":"Jacobson","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.019_bib17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/hum.2006.17.845","article-title":"Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis","volume":"17","author":"Jacobson","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.019_bib18","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1167\/iovs.17-22473","article-title":"Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates","volume":"58","author":"Seitz","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2024.10.019_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/humc.2015.164","article-title":"Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia","volume":"27","author":"Ye","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.10.019_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutatons: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.10.019_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.019_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41575-022-00729-0","article-title":"Gene therapy for liver diseases \u2014 progress and challenges","volume":"20","author":"Zabaleta","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.019_bib23","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200052","article-title":"Liver-Directed Adeno-Associated Virus\u2013Mediated Gene Therapy for Mucopolysaccharidosis Type VI","volume":"1","author":"Brunetti-Pierri","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ymthe.2024.10.019_bib24","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1167\/iovs.15-17398","article-title":"Impact of cationic amino acid transporter 1 on blood-retinal barrier transport of L-ornithine","volume":"56","author":"Kubo","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2024.10.019_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1167\/iovs.06-0398","article-title":"Ornithine transport via cationic amino acid transporter-1 is involved in ornithine cytotoxicity in retinal pigment epithelial cells","volume":"48","author":"Kaneko","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2024.10.019_bib26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2024.10.019_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation\u2013Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2024.10.019_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0092-8674(81)90089-1","article-title":"Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a \u03b32a variable region","volume":"24","author":"Bothwell","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.10.019_bib29","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1089\/hum.1998.9.18-2745","article-title":"Novel Tool for Production and Purification Recombinant Adenoassociated Virus Vectors","volume":"2760","author":"Grimm","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.019_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2144\/03341dd07","article-title":"Optimized production of high-titer recombinant adeno-associated virus in roller bottles","volume":"34","author":"Liu","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2024.10.019_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.1998.9.5-695","article-title":"Factors influencing recombinant adeno-associated virus production","volume":"9","author":"Salvetti","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.019_bib32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.019_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/hgtb.2013.155","article-title":"AAV2\/8 vectors purified from culture medium with a simple and rapid protocol transduce murine liver, muscle, and retina efficiently","volume":"24","author":"Doria","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2024.10.019_bib34","first-page":"125","article-title":"Intraocular Delivery of Recombinant Virus","volume":"47","author":"Liang","year":"2001","journal-title":"Methods Mol. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:11:34Z","timestamp":1765804294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624006804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001624006804"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}